Theriva Biologics Inc. Common Stock TOVX · Stock Open Theriva Biologics Inc. Common Stock in new tab
Theriva Biologics Inc. Common Stock Analysis (TOVX)
Is Theriva Biologics Inc. Common Stock a good investment? Theriva Biologics Inc. Common Stock (TOVX) is currently trading at 0.2340 USD. Market analysts have a consensus price target of 2.50 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 0.16. This relatively low multiple may signal that Theriva Biologics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Theriva Biologics Inc. Common Stock is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.20.
Investor FAQ
Does Theriva Biologics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Theriva Biologics Inc. Common Stock?
Theriva Biologics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of 1.44.
Company Profile
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 8, 2005 | Needs review |
| April 25, 2007 | 0.33 |
| Aug. 13, 2018 | 0.03 |
| July 25, 2022 | 1:10 |
| Aug. 26, 2024 | 1:25 |
Community Discussion